Predictors of response to TNF-α antagonist therapy in Chinese rheumatoid arthritis

Clinical Rheumatology

Volumn 34, Issue 7, 2015, Pages 1203-1210

  Ding, Rui ^a   Li, Ping ^a   Song, Ding ^a   Zhang, Xin ^a   Bi, Liqi ^a  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

ALB; ESR; HAQ; IL 34; Predictor; RA; TNF antagonist

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; INTERLEUKIN 34; INTERLEUKIN 6; INTERLEUKIN 8; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ALBUMINOID; ANTIRHEUMATIC AGENT; INTERLEUKIN DERIVATIVE; INTERLEUKIN-34, HUMAN; MMP3 PROTEIN, HUMAN; TNF PROTEIN, HUMAN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHINESE; CONTROLLED STUDY; CORRELATIONAL STUDY; DAS28; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCULOSKELETAL DISEASE ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RADIOGRAPHY; REFERENCE VALUE; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS DISEASE ACTIVITY INDEX; SERUM; SHARP SCORE; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; CHEMISTRY; CHINA; METABOLISM; QUESTIONNAIRE; YOUNG ADULT;

ADULT; AGED; ALBUMINS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHINA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; INTERLEUKINS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84931571506     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-2973-3     Document Type: Article

References (28)

1. Bathon JM, Martin RW, Fleischmann RM et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586–1593
2. Maini RN, Breedveld FC, Kalden JR et al (2004) Sustained improvement over two years in physical function, structural damages, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50:1051–1065
3. Simsek I (2012) Predictors of Response to TNF inhibitors in rheumatoid arthritis—do we have new tools for personalized medicine? Bull NYU Hospital Joint Dis 70:187–190
4. Smolen JS, Landewé R, Breedveld FC (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509
5. der Broeder A, van de Putte L, Rau R et al (2002) A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29:2288–2298
6. Salgado E, Maneiro JR, Gomez-Reino JJ (2014) Predictors of response to TNF antagonists. Curr Pharm Des 21:221–232
7. Cuchacovich M, Bueno D, Carvajal R, Bravo N, Aguillón JC, Catalán D, Soto L (2014) Clinical parameters and biomarkers for anti-TNF treatment prognosis in rheumatoid arthritis patients. Clin Rheumatol 33:1707–1714
8. Wright HL, Bucknall RC, Moots RJ et al (2012) Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy. Rheumatology (Oxford) 51:451–459
9. Fabre S, Dupuy AM, Dossat N et al (2008) Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol 153:188–195
10. Yuasa S, Yamaguchi H, Nakanishi Y et al (2013) Treatment responses and their predictors in patients with rheumatoid arthritis treated with biological agents. J Med Invest 60:77–90
11. Pomirleanu C, Ancuta C, Miu S et al (2013) A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers. Clin Rheumatol 32:665–670
12. Gonzalez-Alvaro I, Ortiz AM, Tomero EG et al (2007) Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis 66:1675–1678
13. Takahashi R, SalkikoIsojima MU et al (2014) Serum anticyclic citrullinated protein antibody titers are correlated with the response to biological agents in patients with rheumatoid arthritis. Open Access Rheumatol: Res Rev 6:57–64
14. Braun-Moscovici Y, Markovits D, Zinder O et al (2006) Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 33:497–500
15. Nishimoto T, Seta N, Anan R et al (2014) A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis. Clin Exp Rheumatol 32:211–217
16. Dávila-Fajardo CL, Márquez A, Pascual-Salcedo D et al (2014) Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Pharmacogenet Genomics 24:1–5
17. Kayakabe K, Kuroiwa T, Sakurai N et al (2012) Interleukin-1β measurement in stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritis. Rheumatology (Oxford) 51:1639–1643
18. Ribbens C, Andre B, Jaspar JM et al (2000) Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 27:888–893
19. Abhishek A, Butt S, Gadsby K et al (2010) Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers. J Clin Rheumatol 16:15–18
20. Coulthard LR, Taylor JC, Eyre S et al (2011) Genetic variants within the MAP kinase signaling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis 70:98–103
21. Saevarsdottir S, Wedren S, Seddighzadeh M et al (2011) Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 63:26–36
22. Soderlin MK, Petersson IF, Geborek P (2012) The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol 41:1–9
23. van der Heijde D (2000) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 27:261–263
24. Felson DT, Anderson JJ, Boers M et al (1995) American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727–735
25. Ward MM, Guthrie LC, Alba MI (2014) Brief report: rheumatoid arthritis response criteria and patient-reported improvement in arthritis activity: is an American College of Rheumatology twenty percent response meaningful to patients? Arthritis Rheumatol 66:2339–2343
26. Hyrich KL, Watson KD, Silman AJ et al (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Rheumatology 45:1558–1565
27. Hwang SJ, Choi B, Kang SS et al (2012) Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. Arthritis Res Ther 14:R14
28. Wijbrandts CA, Dijkgraaf MGW, Kraan MC et al (2008) The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor a expression in the synovium. Ann Rheum Dis 67:1139–1144